FIELD: biotechnology; medicine.
SUBSTANCE: group of inventions relates to compounds and compositions for inhibiting the expression of growth hormone receptor (GHR). Compound contains a modified oligonucleotide with a length of 18–30 linked nucleosides, which has a nucleotide base sequence containing part of at least 18 continuous nucleotide bases, per 100 % complementary relative to the equal-length nucleotide bases 153921-153940 of nucleic acid of growth hormone receptor SEQ ID NO: 2. Nucleotide base sequence of the modified oligonucleotide is at least 90 % complementary to SEQ ID NO: 2.
EFFECT: said compound and a composition based thereon are suitable for use in reducing the level of GHR mRNA in a human by administering a therapeutically effective amount of the compound or composition to a human having a disease associated with excess of growth hormone such as acromegaly.
20 cl, 131 tbl, 25 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR MODULATION OF ATAXIN 2 EXPRESSION | 2015 |
|
RU2702838C2 |
| MODULATING EXPRESSION OF ANGIOPOIETIN-LIKE PROTEIN 3 | 2014 |
|
RU2706964C2 |
| COMPOUNDS AND METHODS FOR MODULATING EXPRESSION OF DYSTROPHIC MIOTONIN-PROTEINKINASE (DMPK) | 2014 |
|
RU2690333C2 |
| MODULATION OF THE EXPRESSION OF APOLIPOPROTEIN C-III (APOSIII) IN THE PATIENTS WITH LIPODYSTROPHY | 2016 |
|
RU2737719C2 |
| COMPOSITIONS FOR MODULATING EXPRESSION OF SOD-1 | 2015 |
|
RU2704619C2 |
| COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR EXPRESSION B | 2015 |
|
RU2701645C2 |
| MODULATION OF ANDROGEN RECEPTOR EXPRESSION | 2013 |
|
RU2670486C9 |
| MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS | 2014 |
|
RU2661781C2 |
| FACTOR 11 EXPRESSION MODULATION | 2009 |
|
RU2535964C2 |
| ANTISENSE MODULATION OF GCGR EXPRESSION | 2012 |
|
RU2598709C2 |
